Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Fund News: Bill Ackman, Carl Icahn, Citadel Investment Group

Page 1 of 2

Bill Ackman: ‘We Made One Very Big Mistake’ With Valeant And Lost Big Time (CNBC)
Billionaire hedge fund boss Bill Ackman told CNBC on Friday the past 12 months were the “worst period of performance” of his investment career, and the implosion of Valeant Pharmaceuticals was mostly to blame. “It’s almost entirely been driven by Valeant. I’ve never owned a stock down 90 percent,” the Pershing Square Capital Management chief told “Squawk Box,” referring to Valeant’s plunge from a 52-week high of $245 per share to around $18 per share in late June. Since then Valeant has recovered to around $31 per share, as the embattled drugmaker works to regain investor confidence after questions about its pricing strategy and ties to a specialty pharmacy led to wider political and regulatory scrutiny, and hammered the stock.

Bill Ackman, Pershing Square Capital Management, Herbalife

Carl Icahn Mulled Selling Herbalife Stake to Group That Included Bill Ackman (The Wall Street Journal)
Carl Icahn has recently discussed selling his stake in Herbalife Ltd. to a group including the company’s arch-nemesis William Ackman, another surprising twist in a battle between billionaires that has riveted Wall Street for years. Investment bank Jefferies Group LLC has been seeking over the past month to find buyers for Mr. Icahn’s 18% stake, which is worth roughly $1 billion, people familiar with the matter said. The status of the talks and which other investors may be involved wasn’t clear and Mr. Icahn may sell nothing in the end. The fact that he even entertained selling his shares, by far the biggest single stake in Herbalife—and that Mr. Ackman could be a buyer—adds more drama to a tug of war over a once-obscure nutritional-products company that Mr. Ackman says is a pyramid scheme, an allegation it denies.

Citadel Hires ex BlueCrest Portfolio Manager For London Office (Reuters)
Former BlueCrest Capital Management portfolio manager Ashish Goyal is set to join hedge fund manager Citadel, a Citadel spokesman said on Thursday. Goyal will start at Citadel’s London office in November and will be a portfolio manager on its global fixed income team. He will be part of an expansion of the firm’s macroeconomic investing unit, Citadel said. Goyal declined to comment. At BlueCrest until May, Goyal was a portfolio manager for so-called “macro” bets with a focus on emerging markets. BlueCrest, led by Michael Platt, said in December that it would return outside capital and become a private partnership.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!